Happy Friday!
Sept. 13-19 is Balance Awareness Week. It’s intended to bring attention to balance-related vestibular disorders such as Meniere’s disease and vestibular migraine. Looking for ways to help out? Our partners over at VeDA, the Vestibular Disorder Association, have some good ideas about where to start. Duchenne Muscular Dystrophy Awareness Day was last week, and if you’re a patient, caregiver or health care professional who is interested in treatment updates, check out this webinar coordinated by our partners at CureDuchenne.
In this weeks Editor’s Choice, we have some emerging details on the impact of COVID-19 on heart damage. We also have some promising preclinical results in a gene therapy for Fabry Disease. And, finally, the FDA has provided a rare pediatric designation for an experimental diagnostic tool for neuroblastoma. We hope you enjoy your weekend!
COVID-19 and Heart Damage: What You Need to Know
The pandemic continues to present new surprises and challenges to the medicine and science communities.
A Gene Therapy for Fabry Disease Shows Positive Preclinical Results
To determine the safety and efficacy of experimental gene therapy ST-920, researchers first examined the impact of the drug on mouse models of Fabry disease.
An Experimental Diagnostic for Neuroblastoma Earns Rare Pediatric Disease Status
This diagnostic is being developed as an imaging agent for the treatment of neuroblastoma, a rare cancer that primarily impacts children.
